model

LDS Church’s northern Utah ranch is proving to be a model for Western livestock grazing

Livestock grazing has taken a heavy toll on Western rangelands since the arrival of domestic cattle and sheep that were bred for much damper climates.



a man that is standing in the grass: (Brett Prettyman | Tribune file photo) Rick Danvir, wildlife manager for Deseret Land and Livestock Ranch, points out a popular elk area while touring the private land in northern Utah with Boyd Blackwell of the Utah Division of Wildlife Resources, in this 2008 file photo. The 200,000-acre Rich County ranch is one of many large agricultural operations owned by The Church of Jesus Christ of Latter-day Saints around the nation.


© Provided by Salt Lake Tribune
(Brett Prettyman | Tribune file photo) Rick Danvir, wildlife manager for Deseret Land and Livestock Ranch, points out a popular elk area while touring the private land in northern Utah with Boyd Blackwell of the Utah Division of Wildlife Resources, in this 2008 file photo. The 200,000-acre Rich County ranch is one of many large agricultural operations owned by The Church of Jesus Christ of Latter-day Saints around the nation.

These animals, which have contributed greatly to the West’s pioneer heritage, have damaged fragile alpine and desert ecosystems, fouled stream corridors and rearranged native plant communities, environmentalist say.

While they contend public lands grazing is not sustainable in its time-worn form, Utah’s notably dry and cold Monte Cristo

Read More Read more
model

BridgeBio’s en route to proving out its ‘Moneyball’ for biotech model: CEO

BridgeBio Pharma CEO and founder Neil Kumar
BridgeBio Pharma CEO and founder
Neil Kumar, Ph.D. (BridgeBio Pharma)

When Neil Kumar, Ph.D., started BridgeBio Pharma in 2015, he met a lot of rejection. Investor after investor passed on his idea: picking up rare disease treatments “lying fallow” in academia and developing enough of them simultaneously that they would make money. Now, five years, an IPO and more than 20 programs later, BridgeBio is showing its backers what it’s made of.

Kumar chalks the company’s momentum up to two things.

“Initial growth, well, it makes sense for any company. Going from zero to one or two is what anyone will do,” he said. But the ability to go beyond one or two programs to four in phase 3, four more in phase 2 and several in phase 1 or almost in phase 1? That comes down to a set of simple rules BridgeBio repeats over and over, and its

Read More Read more